NASDAQ:ABEO Abeona Therapeutics (ABEO) Stock Price, News & Analysis $6.41 +0.05 (+0.79%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Abeona Therapeutics Stock (NASDAQ:ABEO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Abeona Therapeutics alerts:Sign Up Key Stats Today's Range$6.04▼$6.4350-Day Range$5.12▼$6.7452-Week Range$3.05▼$9.01Volume253,506 shsAverage Volume436,978 shsMarket Capitalization$262.57 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingBuy Company OverviewAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Read More… top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… Abeona Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks69th Percentile Overall ScoreABEO MarketRank™: Abeona Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 368th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAbeona Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbeona Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Abeona Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Abeona Therapeutics are expected to decrease in the coming year, from ($1.28) to ($1.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abeona Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Abeona Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbeona Therapeutics has a P/B Ratio of 10.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Abeona Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.07% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Abeona Therapeutics has recently increased by 3.75%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.03 Percentage of Shares Shorted7.07% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Abeona Therapeutics has recently increased by 3.75%, indicating that investor sentiment is decreasing. News and Social Media1.8 / 5News Sentiment0.21 News SentimentAbeona Therapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Abeona Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for ABEO on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by Institutions80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abeona Therapeutics' insider trading history. Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ABEO Stock News HeadlinesAbeona Therapeutics' (ABEO) Overweight Rating Reiterated at Cantor FitzgeraldOctober 30 at 5:07 AM | americanbankingnews.comAbeona Therapeutics completes Pz-cel BLA resubmission to U.S. FDAOctober 29 at 6:34 PM | markets.businessinsider.comEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.October 31, 2024 | Paradigm Press (Ad)Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug AdministrationOctober 29 at 7:30 AM | globenewswire.comRosalind Advisors, Inc. Expands Stake in Myomo IncOctober 19, 2024 | finance.yahoo.comAbeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...October 10, 2024 | finance.yahoo.comAbeona Therapeutics Targets RDEB Market With Promising Pz-cel TherapyOctober 3, 2024 | seekingalpha.comAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2024 | globenewswire.comSee More Headlines ABEO Stock Analysis - Frequently Asked Questions How have ABEO shares performed this year? Abeona Therapeutics' stock was trading at $5.01 at the beginning of the year. Since then, ABEO shares have increased by 27.9% and is now trading at $6.41. View the best growth stocks for 2024 here. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc (NASDAQ:ABEO) announced its quarterly earnings data on Monday, August, 12th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.42. When did Abeona Therapeutics' stock split? Abeona Therapeutics's stock reverse split on the morning of Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Abeona Therapeutics' major shareholders? Top institutional investors of Abeona Therapeutics include Rosalind Advisors Inc. (4.47%) and abrdn plc (0.80%). Insiders that own company stock include Vishwas Seshadri, Brendan M O'malley, Michael Amoroso, Christine Berni Silverstein, Faith L Charles and Mark Alvino. View institutional ownership trends. How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), CymaBay Therapeutics (CBAY) and General Electric (GE). Company Calendar Last Earnings8/12/2024Today10/31/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CUSIPN/A CIK318306 Webwww.abeonatherapeutics.com Phone214-665-9495Fax214-905-5101EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$21.00 Low Stock Price Target$15.00 Potential Upside/Downside+190.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,190,000.00 Net MarginsN/A Pretax Margin-2,190.26% Return on Equity-237.99% Return on Assets-71.08% Debt Debt-to-Equity Ratio0.22 Current Ratio7.48 Quick Ratio7.48 Sales & Book Value Annual Sales$3.50 million Price / Sales72.56 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book10.33Miscellaneous Outstanding Shares40,963,000Free Float41,018,000Market Cap$253.97 million OptionableOptionable Beta1.53 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ABEO) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.